Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azelnidipine.

Keri Wellington1, Lesley J Scott

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 26, 2003
PubMed
Summary

Azelnidipine effectively controls blood pressure (BP) in hypertensive patients. This dihydropyridine calcium channel antagonist demonstrates significant BP reduction and is well-tolerated, with few adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Azelnidipine is a novel dihydropyridine calcium channel antagonist.
  • It exhibits selectivity for L-type calcium channels.
  • Recently approved in Japan for hypertension treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of azelnidipine in patients with hypertension.
  • To assess its blood pressure-lowering effects in different hypertensive populations.

Main Methods:

  • Clinical trials involving patients with mild-to-moderate hypertension.
  • A 1-year long-term treatment study in 95 patients.
  • A 1-year study adding azelnidipine to existing antihypertensive agents in 172 patients.
  • Randomized, double-blind studies comparing azelnidipine with amlodipine or nitrendipine.

Main Results:

  • Long-term azelnidipine treatment reduced systolic/diastolic BP by 27.8/16.6 mm Hg after 1 year.
  • Addition of azelnidipine significantly reduced BP from 165.7/95.4 mm Hg to 138.2/79.9 mm Hg.
  • Efficacy was comparable to amlodipine and nitrendipine, with similar 24-hour BP control to amlodipine.
  • Generally well tolerated, with common adverse events including headache and hot facial flushes; no reflex tachycardia observed.

Conclusions:

  • Azelnidipine is an effective antihypertensive agent for mild-to-moderate and uncontrolled hypertension.
  • It offers comparable efficacy to other dihydropyridine calcium channel blockers.
  • The drug is generally well-tolerated with a favorable safety profile.

Related Experiment Videos